Yunhai Biotechnology Successfully Completes Strategic Financing

On March 5, 2024, Chengdu Yunhai Tetrahedral Biotechnology Co., Ltd. announced the successful completion of its strategic investment round. This round of financing was led by Chengdu Jiaozhi Modern Urban Industrial Equity Investment Fund (Limited Partnership), with the funding amount reaching several tens of millions of RMB.

Chengdu Yunhai Tetrahedral Biotechnology Co., Ltd. (hereinafter referred to as "Yunhai Biotechnology") is an innovative platform enterprise specializing in tetrahedral nucleic acid technology, headquartered in the Jinniu District of Chengdu. Yunhai Biotechnology is led by Professor Yunfeng Lin and his team from the State Key Laboratory of Oral Diseases. The company has established the Yunhai Tetrahedral Nucleic Acid General Technology Platform based on the team’s invention of the DNA tetrahedral framework nucleic acid drug system. Yunhai Biotechnology manages and operates global patents related to tetrahedral nucleic acids and collaborates with industry partners for research and development, facilitating the translation and commercialization of tetrahedral nucleic acid technology in both pharmaceutical and non-pharmaceutical applications.